(Q36209607)

12 August 2017

1 reference

title

Benefit-risk assessment of raloxifene in postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

12 August 2017

0 references

1 reference

Ann Cranney

1

1 reference

PubMed ID

16048357

12 August 2017

Jonathan D Adachi

series ordinal

2

1 reference

12 August 2017

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

28

1 reference

12 August 2017

8

1 reference

12 August 2017

721-730

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200528080-00006

12 August 2017

0 references

cites work

Effects of raloxifene therapy on the anticoagulant system in postmenopausal women

1 reference

12 December 2020

Early discontinuation of treatment for osteoporosis

1 reference

12 December 2020

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

12 December 2020

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

1 reference

12 December 2020

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

1 reference

12 December 2020

Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis

1 reference

12 December 2020

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation

1 reference

12 December 2020

Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

1 reference

12 December 2020

Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60

1 reference

12 December 2020

Raloxifene: recent information on skeletal and non-skeletal effects

1 reference

12 December 2020

Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism

1 reference

12 December 2020

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

1 reference

12 December 2020

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

12 December 2020

Design and methods of the Raloxifene Use for The Heart (RUTH) study

1 reference

12 December 2020

Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) Scale

1 reference

12 December 2020

Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women

1 reference

12 December 2020

A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate

1 reference

12 December 2020

Cognitive function in postmenopausal women treated with raloxifene

1 reference

12 December 2020

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

1 reference

12 December 2020

Risk of new vertebral fracture in the year following a fracture

1 reference

12 December 2020

Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study

1 reference

12 December 2020

Pharmacokinetics of selective estrogen receptor modulators

1 reference

12 December 2020

Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene

1 reference

12 December 2020

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

12 December 2020

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

1 reference

12 December 2020

Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial

1 reference

12 December 2020

Overview of the main outcomes in breast-cancer prevention trials

1 reference

12 December 2020

Alendronate: an update of its use in osteoporosis

1 reference

12 December 2020

Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study

1 reference

12 December 2020

Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Review on raloxifene: profile of a selective estrogen receptor modulator

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Raloxifene-associated hepatitis

1 reference

12 December 2020

The estrogen receptor: a model for molecular medicine.

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

1 reference

12 December 2020

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

1 reference

12 December 2020

Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Raloxifene causing malabsorption of levothyroxine

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

1 reference

12 December 2020

Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes

1 reference

12 December 2020

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

12 December 2020

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.2165/00002018-200528080-00006

Identifiers

DOI

1 reference

PubMed ID

16048357

Dimensions Publication ID

12 August 2017

0 references

1 reference

PubMed ID

16048357